てんかん（Epilepsy）：グローバル治療薬予測と市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables17
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Classification of Seizures 28
3.2 Etiology and Pathophysiology 29
3.2.1 Etiology 29
3.2.2 Pathophysiology 32
3.2.3 Prognosis 38
3.2.4 Quality of Life 39
4 Epidemiology 40
4.1 Risk Factors and Comorbidities 40
4.1.1 Risk factors in newborns often include brain malformations and lack of oxygen 40
4.1.2 Genetic factors and head trauma are risk factors in adults and children 41
4.1.3 Common seizure triggers include lack of sleep, stress, and photosensitivity 41
4.1.4 Epilepsy comorbidities in adults and children include pain disorders 41
4.1.5 Anxiety and depression are major epilepsy comorbidities 42
4.1.6 Epilepsy with a known cause can be prevented by the avoidance of head injuries 42
4.2 Global Trends 43
4.2.1 United States 44
4.2.2 5EU Markets (France, Germany, Italy, Spain, and UK) 45
4.2.3 Asia 46
4.3 Forecast Methodology 48
4.3.1 Sources Used 49
4.3.2 Forecast Assumptions and Methods 55
4.3.3 Sources Not Used 58
4.4 Epidemiologic Forecast 59
4.4.1 Total Active Prevalent Cases of Epilepsy 59
4.4.2 Total Lifetime Prevalent Cases of Epilepsy 61
4.4.3 Age-Specific Total Active Prevalent Cases of Epilepsy 63
4.4.4 Gender-Specific Total Active Prevalent Cases of Epilepsy 64
4.4.5 Seizure-Specific Total Active Prevalent Cases of Epilepsy 65
4.5 Discussion 66
4.5.1 Conclusion on Epidemiological Trends 66
4.5.2 Limitations of the Analysis 67
4.5.3 Strengths of the Analysis 67
5 Disease Management 68
5.1 Diagnosis 68
5.2 Treatment Guidelines 69
5.3 Clinical Practice 70
5.4 US 77
5.4.1 Diagnosis 77
5.4.2 Clinical Practice 78
5.5 UK 81
5.5.1 Diagnosis 81
5.5.2 Clinical Practice 82
5.6 France 83
5.6.1 Diagnosis 83
5.6.2 Clinical Practice 84
5.7 Germany 86
5.7.1 Diagnosis 86
5.7.2 Clinical Practice 87
5.8 Spain 89
5.8.1 Diagnosis 89
5.8.2 Clinical Practice 90
5.9 Italy 91
5.9.1 Diagnosis 91
5.9.2 Clinical Practice 92
5.10 Japan 94
5.10.1 Diagnosis 94
5.10.2 Clinical Practice 95
5.11 India 96
5.11.1 Diagnosis 96
5.11.2 Clinical Practice 97
5.12 China 99
5.12.1 Diagnosis 99
5.12.2 Clinical Practice 100
6 Competitive Assessment 102
6.1 Overview 102
6.2 Strategic Competitor Assessment 104
6.3 Product Profiles – Major Brands 107
6.3.1 Keppra (levetiracetam) 107
6.3.2 Lamictal (lamotrigine) 113
6.3.3 Lyrica (pregabalin) 119
6.3.4 Vimpat (lacosamide) 123
6.3.5 Zonegran (zonisamide) 128
6.3.6 Banzel/Inovelon (rufinamide) 133
6.3.7 Trobalt/Potiga (retigabine/ezogabine) 137
6.3.8 Zebinix/Aptiom (eslicarbazepine acetate) 142
6.3.9 Fycompa (perampanel) 146
6.3.10 Older-Generation AEDs 149
7 Opportunity and Unmet Need 151
7.1 Overview 151
7.2 Unmet Needs 152
7.2.1 Refractory Epilepsy 152
7.2.2 Safety/Side Effect Profiles 152
7.2.3 Curative/Disease-Modifying Agents 153
7.2.4 Predictive Tools and Need for More Directed Treatments 154
7.2.5 Improved Preclinical Models and Clinical Trial Paradigms 155
7.2.6 Treatment Gap 156
7.3 Unmet Needs Gap Analysis 157
7.4 Opportunities 157
7.4.1 Disease-Modifying Agents 157
7.4.2 Improved Preclinical Models and Clinical Trial Paradigms 157
7.4.3 Treatment Gap 158
8 Pipeline Assessment 159
8.1 Overview 159
8.2 Clinical Trial Mapping 159
8.2.1 Clinical Trials by Country 159
8.3 Clinical Trials by Phase and Trial Status 161
8.4 Strategic Pipeline Assessment 162
8.5 Pipeline by Phases of Development 163
8.5.1 Phase III Pipeline 163
8.5.2 Phase III Pipeline – Reformulations/New Delivery Systems 163
8.5.3 Phase IIb Pipeline 164
8.5.4 Phase II Pipeline 164
8.5.5 Phase I Pipeline 165
8.5.6 Preclinical Pipeline 166
8.5.7 Discovery Pipeline 167
8.6 Pipeline by Mechanism of Action 167
8.7 Promising Drugs in Clinical Development 170
8.7.1 Brivaracetam 171
8.7.2 Ganaxolone 175
8.7.3 VX-765 180
9 Current and Future Players 184
9.1 Overview 184
9.2 Trends in Corporate Strategy 187
9.3 Company Profiles 189
9.3.1 UCB 189
9.3.2 Eisai 191
9.3.3 Pfizer 193
9.3.4 GlaxoSmithKline 195
9.3.5 Novartis 197
9.3.6 Abbott 199
9.3.7 Dainippon Sumitomo Pharma 201
10 Market Outlook 203
10.1 Global Markets 203
10.1.1 Forecast 203
10.1.2 Drivers and Barriers – Global Issues 207
10.2 United States 209
10.2.1 Forecast 209
10.2.2 Key Events 213
10.2.3 Drivers and Barriers 213
10.3 France 215
10.3.1 Forecast 215
10.3.2 Key Events 219
10.3.3 Drivers and Barriers 219
10.4 Germany 221
10.4.1 Forecast 221
10.4.2 Key Events 225
10.4.3 Drivers and Barriers 225
10.5 Italy 227
10.5.1 Forecast 227
10.5.2 Key Events 231
10.5.3 Drivers and Barriers 231
10.6 Spain 233
10.6.1 Forecast 233
10.6.2 Key Events 237
10.6.3 Drivers and Barriers 237
10.7 United Kingdom 239
10.7.1 Forecast 239
10.7.2 Key Events 243
10.7.3 Drivers and Barriers 243
10.8 Japan 246
10.8.1 Forecast 246
10.8.2 Key Events 249
10.8.3 Drivers and Barriers 249
10.9 India 252
10.9.1 Forecast 252
10.9.2 Key Events 255
10.9.3 Drivers and Barriers 255
10.10 China 258
10.10.1 Forecast 258
10.10.2 Key Events 261
10.10.3 Drivers and Barriers 261
11 Appendix 263
11.1 Bibliography 263
11.2 Abbreviations 278
11.3 Methodology 282
11.4 Forecasting Methodology 282
11.4.1 Prevalent Epilepsy Patients 282
11.4.2 Percent Drug-Treated Patients 283
11.4.3 Drugs Included in Each Therapeutic Class Based on MOA 283
11.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates 284
11.4.5 General Pricing Assumptions 286
11.4.6 Individual Drug Assumptions 287
11.4.7 Generic Erosion 300
11.4.8 Pricing of Pipeline Agents 300
11.5 Physicians and Specialists Included in this Study 301
11.6 Primary Research – Prescriber Survey 302
11.7 About the Authors 303
11.7.1 Authors 303
11.7.2 Epidemiologist 304
11.7.3 Global Head of Healthcare 304
11.8 About GlobalData 305
11.9 Disclaimer 305